Abstract
There is growing evidence of the importance of mucosal healing (MH) in ulcerative colitis, but whether or not it should be a future primary treatment goal is still under intense discussion. Within the last decade many clinical trials have focused not only on response and remission rates but also on achievement of MH, while in clinical practice we still make treatment decisions on the basis of clinical symptoms. There is so far no internationally accepted definition of MH and the tools for assessment of MH vary from biomarkers to endoscopy with histological evaluation on the basis of several different scores and indices. This review will focus on present data dealing with methods to assess MH and the importance of MH for the future course of disease, the need for colectomy or risk of developing colorectal cancer and the patient’s quality of life. Many questions remain: How and when do we best assess MH? How rapidly do we need to achieve MH? What is the optimal time point to discontinue treatment after achieving MH? Well defined prospective studies are needed to address these important questions.
Keywords: Biomarkers, cancer risk, clinical outcome, hospitalization, imaging, inflammatory bowel disease, mucosal healing, quality of life, relapse, ulcerative colitis.
Current Drug Targets
Title:Imaging in Inflammatory Bowel Disease Mucosal Healing in Ulcerative Colitis: Relevance for Clinical Outcomes
Volume: 13 Issue: 10
Author(s): Anja Schirbel and Andreas Sturm
Affiliation:
Keywords: Biomarkers, cancer risk, clinical outcome, hospitalization, imaging, inflammatory bowel disease, mucosal healing, quality of life, relapse, ulcerative colitis.
Abstract: There is growing evidence of the importance of mucosal healing (MH) in ulcerative colitis, but whether or not it should be a future primary treatment goal is still under intense discussion. Within the last decade many clinical trials have focused not only on response and remission rates but also on achievement of MH, while in clinical practice we still make treatment decisions on the basis of clinical symptoms. There is so far no internationally accepted definition of MH and the tools for assessment of MH vary from biomarkers to endoscopy with histological evaluation on the basis of several different scores and indices. This review will focus on present data dealing with methods to assess MH and the importance of MH for the future course of disease, the need for colectomy or risk of developing colorectal cancer and the patient’s quality of life. Many questions remain: How and when do we best assess MH? How rapidly do we need to achieve MH? What is the optimal time point to discontinue treatment after achieving MH? Well defined prospective studies are needed to address these important questions.
Export Options
About this article
Cite this article as:
Schirbel Anja and Sturm Andreas, Imaging in Inflammatory Bowel Disease Mucosal Healing in Ulcerative Colitis: Relevance for Clinical Outcomes, Current Drug Targets 2012; 13 (10) . https://dx.doi.org/10.2174/138945012802429750
DOI https://dx.doi.org/10.2174/138945012802429750 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Optimal Human Blood Sampling for Platelet Research
Current Angiogenesis (Discontinued) Pathogenic Genes Selection Model of Genetic Disease based on Network Motifs Slicing Feedback
Current Proteomics Emerging Role and Targeting of Carcinoembryonic Antigen-related Cell Adhesion Molecule 6 (CEACAM6) in Human Malignancies
Clinical Cancer Drugs Prediction by Pharmacogenetics of Safety and Efficacy of Non-Steroidal Anti- Inflammatory Drugs: A Review
Current Drug Metabolism Mechanisms of Action of Imidazoacridinone and Triazoloacridinone Derivatives in View of their Biological Activity
Current Pharmaceutical Analysis Telomere Maintenance Mechanisms in Cancer: Clinical Implications
Current Pharmaceutical Design Natural Polyphenols and their Synthetic Analogs as Emerging Anticancer Agents
Current Drug Targets Notch-Associated MicroRNAs in Cancer
Current Drug Targets Poly(ADP-Ribose) Polymerase-1 (PARP-1) Inhibitors in Cancer Chemotherapy
Recent Patents on Anti-Cancer Drug Discovery The Clinical Perspective on Value of 3D, Thin Slice T2-Weighted Images in 3T Pelvic MRI for Tumors
Current Medical Imaging Animal Venoms have Potential to Treat Cancer
Current Topics in Medicinal Chemistry The Use of Methylphenidate for Physical and Psychological Symptoms in Cancer Patients: A Review
Current Drug Targets Current Pharmacological Approaches to Prevent and Treat Post- Menopausal Osteoporosis
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Anticancer Potential of Pulicaria crispa Extract on Human Breast Cancer MDA-MB-231 Cells
Letters in Drug Design & Discovery Recent Advances Involving Palladium (II) Complexes for the Cancer Therapy
Anti-Cancer Agents in Medicinal Chemistry Smad-Signaling in Mammary Gland Development and Tumorigenesis
Current Signal Transduction Therapy The CXCL12/CXCR4 Axis as a Therapeutic Target in Cancer and HIV-1 Infection
Current Medicinal Chemistry Fullerenes: From Carbon to Nanomedicine
Mini-Reviews in Medicinal Chemistry PEGylation: An Overview and Recent Advances Reported in the Patent Literature
Recent Patents on Chemical Engineering Tumor Stem Cell Niches: A New Functional Framework for the Action of Anticancer Drugs
Recent Patents on Anti-Cancer Drug Discovery